cangrelor   Click here for help

GtoPdb Ligand ID: 1776

Synonyms: AR-C69931MX | ARL69931 | Kengreal® | Kengrexal®
Approved drug
cangrelor is an approved drug (FDA & EMA (2015))
Compound class: Synthetic organic
Comment: Cangrelor is an intravenously administered antiplatelet compound.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cangrelor

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 16
Hydrogen bond donors 7
Rotatable bonds 16
Topological polar surface area 335.94
Molecular weight 774.95
XLogP -0.41
No. Lipinski's rules broken 3
Click here for help
Canonical SMILES CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2C1OC(C(C1O)O)COP(=O)(OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O
Isomeric SMILES CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COP(=O)(OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O
InChI InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
No information available.
Summary of Clinical Use Click here for help
In June 2015, cangrelor was apprioved as an adjunct which may be used to prevent the formation of harmful blood clots in the coronary arteries in patients undergoing percutaneous coronary intervention.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Cangrelor is a P2Y12 inhibitor [6]. Inhibition of P2Y12 reduces ADP-mediated platelet activation and aggregation. This compound has a more rapid onset and reversal of action than currently approved antiplatelet drugs [2], making it a potentially effective bridging therapy in patients requiring surgical intervention.